To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects with Stable Coronary Artery Disease

Study identifier:D5780C00002

ClinicalTrials.gov identifier:NCT02601560

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects with Stable Coronary Artery Disease

Medical condition

Coronary artery disease

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

48

Study type

Interventional

Age

40 Years - 75 Years

Date

Study Start Date: 03 Dec 2015
Primary Completion Date: 20 Aug 2016
Study Completion Date: 03 Nov 2016

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Sequential Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2018 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria